BR112012004377A2 - terapia de reposição enzimática com progressão de dose para tratamento de deficiência de esfingomielinase ácida. - Google Patents

terapia de reposição enzimática com progressão de dose para tratamento de deficiência de esfingomielinase ácida.

Info

Publication number: BR112012004377A2
Authority: BR; Brazil
Prior art keywords: progressing; dose; treatment; replacement therapy; enzyme replacement
Prior art date: 2009-08-28

Application number

BR112012004377A

Other languages

English (en)

Inventor

H Schuchman Edward

f cox Gerald

M Murray James

P Andrews Laura

J Desnick Robert

Original Assignee

Genzyme Corp

Mount Sinai School Of Medicine Of New York Univ

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-08-28

Filing date

2010-08-28

Publication date

2017-12-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012004377(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-08-28 Application filed by Genzyme Corp, Mount Sinai School Of Medicine Of New York Univ filed Critical Genzyme Corp

2017-12-12 Publication of BR112012004377A2 publication Critical patent/BR112012004377A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Dermatology (AREA)

BR112012004377A 2009-08-28 2010-08-28 terapia de reposição enzimática com progressão de dose para tratamento de deficiência de esfingomielinase ácida. BR112012004377A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23811309P	2009-08-28	2009-08-28
PCT/US2010/047057 WO2011025996A2 (en)	2009-08-28	2010-08-28	Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency

Publications (1)

Publication Number	Publication Date
BR112012004377A2 true BR112012004377A2 (pt)	2017-12-12

Family

ID=43625265

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112012004377A BR112012004377A2 (pt)	2009-08-28	2010-08-28	terapia de reposição enzimática com progressão de dose para tratamento de deficiência de esfingomielinase ácida.

Country Status (27)

Country	Link
US (9)	US8349319B2 (pt)
EP (3)	EP3482767B1 (pt)
JP (7)	JP5955219B2 (pt)
KR (5)	KR102608551B1 (pt)
CN (3)	CN105999238A (pt)
AU (5)	AU2010286550B2 (pt)
BR (1)	BR112012004377A2 (pt)
CA (1)	CA2773133A1 (pt)
CL (1)	CL2012000495A1 (pt)
CY (1)	CY1122128T1 (pt)
DK (2)	DK3482767T3 (pt)
ES (2)	ES2902229T3 (pt)
FR (1)	FR22C1062I2 (pt)
HR (2)	HRP20211992T1 (pt)
HU (3)	HUE057440T2 (pt)
IL (4)	IL314807A (pt)
LT (2)	LT2470199T (pt)
MX (1)	MX356873B (pt)
NL (1)	NL301211I2 (pt)
NO (1)	NO2022054I1 (pt)
PL (2)	PL2470199T3 (pt)
PT (2)	PT2470199T (pt)
RU (3)	RU2569744C2 (pt)
SI (2)	SI3482767T1 (pt)
TR (1)	TR201911293T4 (pt)
WO (1)	WO2011025996A2 (pt)
ZA (2)	ZA201201435B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8889127B2 (en)	2004-07-01	2014-11-18	Icahn School Of Medicine At Mount Sinai	Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en)	2007-03-13	2008-09-18	Michael Blomquist	Basal rate testing using frequent blood glucose input
US7751907B2 (en)	2007-05-24	2010-07-06	Smiths Medical Asd, Inc.	Expert system for insulin pump therapy
US8221345B2 (en)	2007-05-30	2012-07-17	Smiths Medical Asd, Inc.	Insulin pump based expert system
PT2158322T (pt)	2007-06-06	2017-08-09	Genzyme Corp	Terapia genética para doenças do armazenamento lisossomal
HRP20211992T1 (hr) *	2009-08-28	2022-04-01	Icahn School Of Medicine At Mount Sinai	Zamjenska enzimska terapija povećanjem doze za liječenje nedostatka kiseline sfingomijelinaze
US8882701B2 (en) *	2009-12-04	2014-11-11	Smiths Medical Asd, Inc.	Advanced step therapy delivery for an ambulatory infusion pump and system
EP2571997A2 (en)	2010-05-21	2013-03-27	Ohmx Corporation	Enzymatic activity of psa as diagnostic marker for prostate cancer
PL2685986T3 (pl)	2011-03-18	2020-07-27	Genzyme Corporation	Inhibitor syntazy glukozyloceramidowej
PL2753346T3 (pl)	2011-09-07	2020-10-19	Mount Sinai School Of Medicine	Ceramidaza i różnicowanie komórek
US9910033B2 (en)	2011-11-15	2018-03-06	Centogene Ag	Method for the diagnosis of Niemann-Pick disease
CA2874146C (en)	2012-06-01	2023-03-21	Icahn School Of Medicine At Mount Sinai	Ceramide levels in the treatment and prevention of infections
MA37975B2 (fr)	2012-09-11	2021-03-31	Genzyme Corp	Inhibiteurs de synthase de glucosylcéramide
ES2739811T3 (es) *	2013-03-14	2020-02-04	Icahn School Med Mount Sinai	Composiciones terapéuticas de ceramidasa ácida y métodos de fabricación y uso de ellas
JO3713B1 (ar)	2013-03-15	2021-01-31	Genzyme Corp	أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
CA2912274A1 (en) *	2013-05-14	2014-11-20	Centogene Ag	Method for the diagnosis of niemann-pick disease
CN115128287A (zh) *	2013-06-07	2022-09-30	建新公司	酸性鞘磷脂酶病症的标志物及其用途
JP6984854B2 (ja) *	2015-10-08	2021-12-22	国立大学法人千葉大学	ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
US10569016B2 (en)	2015-12-29	2020-02-25	Tandem Diabetes Care, Inc.	System and method for switching between closed loop and open loop control of an ambulatory infusion pump
KR20200044064A (ko) *	2017-08-24	2020-04-28	사노피	산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료
CA3076369A1 (en)	2017-10-02	2019-04-11	Denali Therapeutics Inc.	Fusion proteins comprising enzyme replacement therapy enzymes
UY38238A (es) *	2018-05-25	2019-12-31	Genzyme Corp	Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
TW202142236A (zh)	2020-02-03	2021-11-16	美商健臻公司	用於治療與溶體儲積症相關的神經症狀之方法
MX2023001014A (es)	2020-07-24	2023-03-01	Genzyme Corp	Composiciones farmaceuticas que comprenden venglustat.

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4082781A (en)	1976-06-04	1978-04-04	The United States Of America As Represented By The Department Of Health, Education And Welfare	Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US4039388A (en)	1976-06-04	1977-08-02	The United States Of America As Represented By The Government	Diagnostic test for Niemann-Pick disease
IL74761A0 (en)	1984-04-13	1985-06-30	Hughes Howard Med Inst	Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) *	1987-10-02	1989-09-05	Capozzola Carl A	Identification tag
US5047335A (en)	1988-12-21	1991-09-10	The Regents Of The University Of Calif.	Process for controlling intracellular glycosylation of proteins
US5549892A (en)	1988-12-23	1996-08-27	Genzyme Corporation	Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en)	1991-05-03	1998-06-30	Mount Sinai Medical Center	Acid sphingomyelinase gene
US5612487A (en)	1991-08-26	1997-03-18	Edible Vaccines, Inc.	Anti-viral vaccines expressed in plants
US6034298A (en)	1991-08-26	2000-03-07	Prodigene, Inc.	Vaccines expressed in plants
US5484719A (en)	1991-08-26	1996-01-16	Edible Vaccines, Inc.	Vaccines produced and administered through edible plants
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US5716614A (en)	1994-08-05	1998-02-10	Molecular/Structural Biotechnologies, Inc.	Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
ATE426031T1 (de)	1995-09-14	2009-04-15	Virginia Tech Intell Prop	Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen
JP2820106B2 (ja)	1996-02-29	1998-11-05	日本電気株式会社	トラヒックシェーパ装置
IL155588A0 (en)	2003-04-27	2003-11-23	Metabogal Ltd	Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en)	1996-09-26	2005-02-10	Metabogal Ltd.	Cell/tissue culturing device, system and method
CN100410268C (zh)	1998-12-23	2008-08-13	博伊斯汤普生植物研究所	免疫原性的乙型肝炎表面抗原在转基因植物中的表达
US6534300B1 (en)	1999-09-14	2003-03-18	Genzyme Glycobiology Research Institute, Inc.	Methods for producing highly phosphorylated lysosomal hydrolases
AU2001250856A1 (en)	2000-03-17	2001-10-03	Charles Arntzen	Expression of recombinant human acetylcholinesterase in transgenic plants
US20020095135A1 (en) *	2000-06-19	2002-07-18	David Meeker	Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en)	2000-08-18	2006-11-21	Shire Human Genetic Therapies, Inc.	High mannose proteins and methods of making high mannose proteins
AU2001286636A1 (en)	2000-08-25	2002-03-13	Lysometrix Corporation	Method for assaying the activity of lysosomal enzymes
US7001994B2 (en)	2001-01-18	2006-02-21	Genzyme Corporation	Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en)	2001-01-18	2010-05-25	Genzyme Corporation	Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
CA2445577C (en)	2001-04-30	2012-07-03	Symbiontics, Inc.	Subcellular targeting of therapeutic proteins
US7560424B2 (en)	2001-04-30	2009-07-14	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
IES20011101A2 (en) *	2001-12-21	2003-06-25	Japkinstill Services Ltd	A Bi-directional Messaging System
WO2003086452A2 (en)	2002-04-05	2003-10-23	Genzyme Corporation	Methods of enhancing lysosomal storage disease therapy
US7585518B2 (en)	2002-11-19	2009-09-08	Kimberly-Clark Worldwide, Inc.	Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en)	2002-11-27	2008-06-17	The Regents Of The University Of California	Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en)	2003-04-27	2011-05-31	Protalix Ltd.	Human lysosomal proteins from plant cell culture
BRPI0411291A (pt)	2003-06-12	2006-08-01	Genzyme Corp	esfingomielinase acida humana modificada tendo atividade aumentada e métodos para a fabricação da mesma
US20050026823A1 (en) *	2003-06-20	2005-02-03	Biomarin Pharmaceutical Inc.	Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) *	2003-08-29	2008-10-28	Biomarin Pharmaceutical Inc.	Delivery of therapeutic compounds to the brain and other tissues
BRPI0416434A (pt)	2003-11-25	2007-02-21	Sinai School Medicine	métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina
MX2007004414A (es)	2004-10-13	2007-09-25	Protalix Ltd	Sistema y metodo para la produccion de anticuerpos en cultivos de celulas de plantas.
US7615224B2 (en)	2004-12-02	2009-11-10	Women's And Children's Hospital	Multiplex-bead complex for determination of lysosomal storage disorders
KR20080082984A (ko)	2005-12-15	2008-09-12	더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕	혈장 및 조직의 스핑고마이엘린 및 포스파티딜콜린의효소적 측정 방법
AR059089A1 (es) *	2006-01-20	2008-03-12	Genzyme Corp	Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
EP1981546B1 (en)	2006-02-06	2014-06-04	The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center	Enzyme replacement therapy for treating lysosomal storage diseases
HUE040490T2 (hu) *	2006-02-09	2019-03-28	Genzyme Corp	Lassú intraventrikuláris szállítás
EP1984405A4 (en)	2006-02-13	2010-06-30	Fraunhofer Usa Inc	INFLUENZA ANTIGENS, VACCINE COMPOSITIONS AND ASSOCIATED METHODS
JP5302189B2 (ja)	2007-04-27	2013-10-02	長瀬産業株式会社	スフィンゴミエリナーゼ
WO2010015816A2 (en)	2008-08-06	2010-02-11	Summit Corporation Plc	Treatment of lysosomal storage disorders and other proteostatic diseases
CA2747230C (en)	2008-12-16	2019-06-11	Genzyme Corporation	Oligosaccharide-protein conjugates
HRP20211992T1 (hr) *	2009-08-28	2022-04-01	Icahn School Of Medicine At Mount Sinai	Zamjenska enzimska terapija povećanjem doze za liječenje nedostatka kiseline sfingomijelinaze
WO2012177778A1 (en) *	2011-06-20	2012-12-27	Mount Sinai School Of Medicine	Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders
CN115128287A (zh) *	2013-06-07	2022-09-30	建新公司	酸性鞘磷脂酶病症的标志物及其用途
KR20200044064A (ko) *	2017-08-24	2020-04-28	사노피	산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료

2010
- 2010-08-28 HR HRP20211992TT patent/HRP20211992T1/hr unknown
- 2010-08-28 RU RU2012111823/15A patent/RU2569744C2/ru active
- 2010-08-28 ES ES18199358T patent/ES2902229T3/es active Active
- 2010-08-28 US US12/870,790 patent/US8349319B2/en active Active
- 2010-08-28 LT LTEP10812683.0T patent/LT2470199T/lt unknown
- 2010-08-28 IL IL314807A patent/IL314807A/en unknown
- 2010-08-28 CN CN201610404696.3A patent/CN105999238A/zh active Pending
- 2010-08-28 HU HUE18199358A patent/HUE057440T2/hu unknown
- 2010-08-28 HU HUE10812683A patent/HUE046598T2/hu unknown
- 2010-08-28 CL CL2012000495A patent/CL2012000495A1/es unknown
- 2010-08-28 EP EP18199358.5A patent/EP3482767B1/en active Active
- 2010-08-28 RU RU2015145255A patent/RU2731616C2/ru active
- 2010-08-28 CN CN2010800439108A patent/CN102596232A/zh active Pending
- 2010-08-28 EP EP10812683.0A patent/EP2470199B1/en active Active
- 2010-08-28 KR KR1020227023712A patent/KR102608551B1/ko active IP Right Grant
- 2010-08-28 PL PL10812683T patent/PL2470199T3/pl unknown
- 2010-08-28 CA CA2773133A patent/CA2773133A1/en active Pending
- 2010-08-28 WO PCT/US2010/047057 patent/WO2011025996A2/en active Application Filing
- 2010-08-28 ES ES10812683T patent/ES2738859T3/es active Active
- 2010-08-28 DK DK18199358.5T patent/DK3482767T3/da active
- 2010-08-28 MX MX2012002449A patent/MX356873B/es active IP Right Grant
- 2010-08-28 KR KR1020207008342A patent/KR20200034828A/ko not_active IP Right Cessation
- 2010-08-28 EP EP21200695.1A patent/EP3998078A1/en active Pending
- 2010-08-28 JP JP2012527054A patent/JP5955219B2/ja active Active
- 2010-08-28 KR KR1020237040891A patent/KR20230164773A/ko active Application Filing
- 2010-08-28 CN CN201610403228.4A patent/CN106047835A/zh active Pending
- 2010-08-28 AU AU2010286550A patent/AU2010286550B2/en active Active
- 2010-08-28 PT PT10812683T patent/PT2470199T/pt unknown
- 2010-08-28 TR TR2019/11293T patent/TR201911293T4/tr unknown
- 2010-08-28 PL PL18199358T patent/PL3482767T3/pl unknown
- 2010-08-28 SI SI201032100T patent/SI3482767T1/sl unknown
- 2010-08-28 KR KR1020127005293A patent/KR102094253B1/ko active IP Right Grant
- 2010-08-28 LT LTEP18199358.5T patent/LT3482767T/lt unknown
- 2010-08-28 SI SI201031915T patent/SI2470199T1/sl unknown
- 2010-08-28 IL IL300625A patent/IL300625B1/en unknown
- 2010-08-28 BR BR112012004377A patent/BR112012004377A2/pt not_active Application Discontinuation
- 2010-08-28 PT PT181993585T patent/PT3482767T/pt unknown
- 2010-08-28 KR KR1020217026374A patent/KR102608546B1/ko active IP Right Grant
- 2010-08-28 DK DK10812683.0T patent/DK2470199T3/da active
2012
- 2012-02-26 IL IL218324A patent/IL218324B/en active IP Right Grant
- 2012-02-27 ZA ZA2012/01435A patent/ZA201201435B/en unknown
- 2012-11-16 US US13/679,623 patent/US8709408B2/en active Active
- 2012-11-16 US US13/679,583 patent/US8658162B2/en active Active
2014
- 2014-01-16 US US14/156,894 patent/US9114139B2/en active Active
2015
- 2015-07-08 US US14/793,838 patent/US9655954B2/en active Active
2016
- 2016-02-26 ZA ZA2016/01362A patent/ZA201601362B/en unknown
- 2016-03-03 JP JP2016041242A patent/JP6251307B2/ja active Active
- 2016-08-17 AU AU2016216625A patent/AU2016216625B2/en active Active
2017
- 2017-04-12 US US15/485,604 patent/US10188705B2/en active Active
- 2017-11-24 JP JP2017226255A patent/JP2018076322A/ja active Pending
2018
- 2018-06-12 AU AU2018204156A patent/AU2018204156B2/en active Active
- 2018-12-04 US US16/209,336 patent/US20190151419A1/en not_active Abandoned
2019
- 2019-05-27 IL IL266915A patent/IL266915B2/en unknown
- 2019-07-29 CY CY20191100808T patent/CY1122128T1/el unknown
- 2019-07-31 HR HRP20191385 patent/HRP20191385T1/hr unknown
2020
- 2020-01-17 JP JP2020005901A patent/JP6952810B2/ja active Active
- 2020-05-26 US US16/883,407 patent/US20210077593A1/en not_active Abandoned
- 2020-09-02 RU RU2020128994A patent/RU2020128994A/ru unknown
- 2020-10-13 AU AU2020256322A patent/AU2020256322B2/en active Active
2021
- 2021-09-28 JP JP2021157902A patent/JP7167281B2/ja active Active
2022
- 2022-02-18 US US17/675,474 patent/US20220305091A1/en active Pending
- 2022-10-26 JP JP2022171242A patent/JP7395693B2/ja active Active
- 2022-12-01 NO NO2022054C patent/NO2022054I1/no unknown
- 2022-12-08 HU HUS2200050C patent/HUS2200050I1/hu unknown
- 2022-12-15 FR FR22C1062C patent/FR22C1062I2/fr active Active
- 2022-12-20 NL NL301211C patent/NL301211I2/nl unknown
2023
- 2023-11-29 JP JP2023201609A patent/JP2024026214A/ja active Pending
2024
- 2024-02-20 AU AU2024201085A patent/AU2024201085A1/en active Pending

Also Published As

Publication number	Publication date
EP2470199A4 (en)	2013-03-27
IL218324B (en)	2019-05-30
IL218324A0 (en)	2012-04-30
US8658162B2 (en)	2014-02-25
NO2022054I1 (no)	2022-12-01
RU2569744C2 (ru)	2015-11-27
RU2012111823A (ru)	2013-10-10
IL300625B1 (en)	2024-09-01
KR20230164773A (ko)	2023-12-04
DK2470199T3 (da)	2019-08-05
PT2470199T (pt)	2019-08-07
PL2470199T3 (pl)	2019-11-29
JP2020090513A (ja)	2020-06-11
JP2013502933A (ja)	2013-01-31
HRP20191385T1 (hr)	2019-11-01
IL266915B2 (en)	2023-07-01
US20210077593A1 (en)	2021-03-18
US20190151419A1 (en)	2019-05-23
EP3482767B1 (en)	2021-10-06
IL266915A (en)	2019-07-31
US20130078230A1 (en)	2013-03-28
AU2020256322B2 (en)	2024-02-29
JP2024026214A (ja)	2024-02-28
PT3482767T (pt)	2021-12-29
HRP20211992T1 (hr)	2022-04-01
IL314807A (en)	2024-10-01
US8709408B2 (en)	2014-04-29
US20220305091A1 (en)	2022-09-29
EP2470199B1 (en)	2019-05-22
HUE046598T2 (hu)	2020-03-30
CY1122128T1 (el)	2020-11-25
LT2470199T (lt)	2019-10-10
AU2020256322A1 (en)	2020-11-12
AU2018204156B2 (en)	2020-07-16
AU2024201085A1 (en)	2024-03-07
CA2773133A1 (en)	2011-03-03
US20130078231A1 (en)	2013-03-28
WO2011025996A9 (en)	2011-08-25
HUS2200050I1 (hu)	2022-12-28
WO2011025996A3 (en)	2012-03-15
US8349319B2 (en)	2013-01-08
US20140335070A1 (en)	2014-11-13
KR102608546B1 (ko)	2023-12-04
CL2012000495A1 (es)	2014-02-07
US10188705B2 (en)	2019-01-29
KR102094253B1 (ko)	2020-03-31
AU2010286550B2 (en)	2016-05-19
CN106047835A (zh)	2016-10-26
FR22C1062I1 (fr)	2023-02-03
AU2016216625A1 (en)	2016-09-15
JP5955219B2 (ja)	2016-07-20
SI3482767T1 (sl)	2022-03-31
ZA201201435B (en)	2020-05-27
EP2470199A2 (en)	2012-07-04
MX2012002449A (es)	2012-03-14
US20160120957A1 (en)	2016-05-05
AU2010286550A1 (en)	2012-03-15
WO2011025996A2 (en)	2011-03-03
US9114139B2 (en)	2015-08-25
KR20200034828A (ko)	2020-03-31
DK3482767T3 (da)	2021-12-20
KR20210107153A (ko)	2021-08-31
JP6952810B2 (ja)	2021-10-20
NL301211I2 (nl)	2023-02-02
RU2020128994A (ru)	2022-03-02
PL3482767T3 (pl)	2022-02-14
ES2738859T3 (es)	2020-01-27
IL266915B1 (en)	2023-03-01
AU2018204156A1 (en)	2018-06-28
CN102596232A (zh)	2012-07-18
EP3482767A1 (en)	2019-05-15
RU2731616C2 (ru)	2020-09-07
JP2018076322A (ja)	2018-05-17
HUE057440T2 (hu)	2022-05-28
SI2470199T1 (sl)	2019-11-29
MX356873B (es)	2018-06-18
KR20120081077A (ko)	2012-07-18
CN105999238A (zh)	2016-10-12
US9655954B2 (en)	2017-05-23
LT3482767T (lt)	2022-01-10
JP2016153408A (ja)	2016-08-25
KR102608551B1 (ko)	2023-12-04
AU2016216625B2 (en)	2018-07-05
JP2022003065A (ja)	2022-01-11
JP7167281B2 (ja)	2022-11-08
US20110052559A1 (en)	2011-03-03
FR22C1062I2 (fr)	2023-12-29
NL301211I1 (nl)	2022-12-28
JP2023012499A (ja)	2023-01-25
TR201911293T4 (tr)	2019-08-21
JP7395693B2 (ja)	2023-12-11
ZA201601362B (en)	2017-05-31
EP3998078A1 (en)	2022-05-18
US20180055916A1 (en)	2018-03-01
IL300625A (en)	2023-04-01
ES2902229T3 (es)	2022-03-25
JP6251307B2 (ja)	2017-12-20
KR20220104271A (ko)	2022-07-26
RU2015145255A3 (pt)	2019-08-12
RU2015145255A (ru)	2019-01-11

Publication	Publication Date	Title
BR112012004377A2 (pt)	2017-12-12	terapia de reposição enzimática com progressão de dose para tratamento de deficiência de esfingomielinase ácida.
IL259475A (en)	2018-07-31	Combined therapy for the treatment of diabetes
BRPI0807987A2 (pt)	2014-06-24	Terapia de combinação para tratamento de distúrbios imunes.
BRPI0919288A2 (pt)	2015-12-15	teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI1012116A2 (pt)	2016-03-15	composição farmacêutica para o tratamento de doenças cardíacas
BRPI0915105A2 (pt)	2019-09-24	composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer
BRPI0816712A2 (pt)	2016-11-08	terapia de intervalo para o tratamento de tinnitus
BRPI0911577A8 (pt)	2018-03-06	derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI1009783A2 (pt)	2016-03-08	compostos para o tratamento de distúrbios metabólicos.
BRPI0906606A2 (pt)	2015-07-14	Tratamento terapêutico para condições do pulmão.
GB0906159D0 (en)	2009-05-20	Drug combination for the treatment of proteostatic diseases
IL260078B (en)	2020-10-29	Therapy used to treat Gaucher disease
BR112013004683A2 (pt)	2016-05-10	"conjunto de cateter para tratamento de nervo"
BR112012002267A2 (pt)	2016-11-08	compostos para o tratamento de inflamação.
AU2008902119A0 (en)	2008-05-15	Stimulation system for the treatment of tinnitus

Legal Events

Date	Code	Title	Description
2018-04-10	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-11-12	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-10-20	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-11-10	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-03-02	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2021-06-08	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2021-08-03	B350	Update of information on the portal [chapter 15.35 patent gazette]
2021-08-17	B350	Update of information on the portal [chapter 15.35 patent gazette]
2022-03-15	B25G	Requested change of headquarter approved	Owner name: GENZYME CORPORATION (US) ; MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US)
2022-04-12	B09B	Patent application refused [chapter 9.2 patent gazette]
2023-10-03	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.